

Accepted Manuscript

Efficacy and safety of fezakinumab (an anti-IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments - A randomized, double-blind, phase 2a trial

Emma Guttman-Yassky, MD, PhD, Patrick M. Brunner, MD, Avidan U. Neumann, PhD, Saakshi Khattri, MD, Ana B. Pavel, PhD, Kunal Malik, BA, Giselle K. Singer, BS, Danielle Baum, Patricia Gilleaudeau, Mary Sullivan-Whalen, Sharon Rose, MD, Shelbi Jim On, MD, Xuan Li, BA, Judilyn Fuentes-Duculan, MD, Yeriel Estrada, BS, Sandra Garcet, PhD, Claudia Traidl-Hoffmann, MD, James G. Krueger, MD, PhD, Mark G. Lebwohl, MD

PII: S0190-9622(18)30101-4

DOI: [10.1016/j.jaad.2018.01.016](https://doi.org/10.1016/j.jaad.2018.01.016)

Reference: YMJD 12266

To appear in: *Journal of the American Academy of Dermatology*

Received Date: 13 November 2017

Revised Date: 5 January 2018

Accepted Date: 9 January 2018

Please cite this article as: Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Rose S, Jim On S, Li X, Fuentes-Duculan J, Estrada Y, Garcet S, Traidl-Hoffmann C, Krueger JG, Lebwohl MG, Efficacy and safety of fezakinumab (an anti-IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments - A randomized, double-blind, phase 2a trial, *Journal of the American Academy of Dermatology* (2018), doi: 10.1016/j.jaad.2018.01.016.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Article type: Original article

Title: Efficacy and safety of fezakinumab (an anti-IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments - A randomized, double-blind, phase 2a trial.

Emma Guttman-Yassky, MD, PhD,^{1,2} Patrick M. Brunner MD,² Avidan U. Neumann, PhD,^{3,4,5} Saakshi Khattri, MD,¹ Ana B. Pavel, PhD,¹ Kunal Malik, BA,¹ Giselle K. Singer, BS,¹ Danielle Baum,¹ Patricia Gilleaudeau,² Mary Sullivan-Whalen,² Sharon Rose, MD,¹ Shelbi Jim On, MD,¹ Xuan Li, BA,² Judilyn Fuentes-Duculan, MD,² Yeriel Estrada, BS,¹ Sandra Garcet, PhD,² Claudia Traidl-Hoffmann, MD,^{3,6} James G. Krueger, MD, PhD,² Mark G. Lebwohl, MD¹

¹ Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

² Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA

³ Institute of Environmental Medicine, UNIKA-T, Technical University Munich and Helmholtz Zentrum München - German Research Center for Environmental Health, Augsburg, Germany

⁴ Swiss Institute of Allergy and Asthma Research (SIAF), University of Zürich, Davos, Switzerland

Download English Version:

<https://daneshyari.com/en/article/8715069>

Download Persian Version:

<https://daneshyari.com/article/8715069>

[Daneshyari.com](https://daneshyari.com)